ADENINKONJUGATFORBINDELSER OG DERES ANVENDELSE SOM VACCINEADJUVANSER

The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L1, L2, X1, R1, R2, R3, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in thera...

Full description

Saved in:
Bibliographic Details
Main Authors MURALIDHARA, Bilikallahalli K, NISHIO, Yukihiro, WONG, Marcus, BAN, Hitoshi, MALYALA, Padma
Format Patent
LanguageDanish
Published 20.07.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L1, L2, X1, R1, R2, R3, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in therapy, for example as vaccine adjuvants. The present specification also relates to a process for preparing adenine conjugate compounds and pharmaceutically acceptable salts thereof, and to pharmaceutical compositions comprising adenine conjugate compounds and their pharmaceutically acceptable salts.
Bibliography:Application Number: DK20160782095T